CLINICAL TRIALS PROFILE FOR INVEGA SUSTENNA
✉ Email this page to a colleague
All Clinical Trials for invega sustenna
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01136772 ↗ | A Comparison of Long-acting Injectable Medications for Schizophrenia | Completed | Duke University | Phase 4 | 2011-03-01 | The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs). |
| NCT01136772 ↗ | A Comparison of Long-acting Injectable Medications for Schizophrenia | Completed | National Institute of Mental Health (NIMH) | Phase 4 | 2011-03-01 | The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs). |
| NCT01136772 ↗ | A Comparison of Long-acting Injectable Medications for Schizophrenia | Completed | University of North Carolina, Chapel Hill | Phase 4 | 2011-03-01 | The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs). |
| NCT01136772 ↗ | A Comparison of Long-acting Injectable Medications for Schizophrenia | Completed | New York State Psychiatric Institute | Phase 4 | 2011-03-01 | The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs). |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for invega sustenna
Condition Name
Clinical Trial Locations for invega sustenna
Trials by Country
Clinical Trial Progress for invega sustenna
Clinical Trial Phase
Clinical Trial Sponsors for invega sustenna
Sponsor Name
